TY - JOUR
T1 - Postinfectious Pulmonary Complications
T2 - Establishing Research Priorities to Advance the Field An Official American Thoracic Society Workshop Report
AU - American Thoracic Society Assembly on Pulmonary Infections and Tuberculosis
AU - Auld, Sara C.
AU - Sheshadri, Ajay
AU - Alexander-Brett, Jennifer
AU - Aschner, Yael
AU - Barczak, Amy K.
AU - Basil, Maria C.
AU - Cohen, Keira A.
AU - Cruz, Charles Dela
AU - McGroder, Claire
AU - Restrepo, Marcos I.
AU - Ridge, Karen M.
AU - Schnapp, Lynn M.
AU - Traber, Katrina
AU - Wunderink, Richard G.
AU - Zhang, David
AU - Ziady, Assem
AU - Attia, Engi F.
AU - Carter, Jane
AU - Chalmers, James D.
AU - Crothers, Kristina
AU - Feldman, Charles
AU - Jones, Barbara E.
AU - Kaminski, Naftali
AU - Keane, Joseph
AU - Lewinsohn, David
AU - Metersky, Mark
AU - Mizgerd, Joseph P.
AU - Morris, Alison
AU - Ramirez, Julio
AU - Samarasinghe, Amali E.
AU - Staitieh, Bashar S.
AU - Stek, Cari
AU - Sun, Jie
AU - Evans, Scott E.
N1 - Publisher Copyright:
Copyright © 2024 by the American Thoracic Society.
PY - 2024/9/1
Y1 - 2024/9/1
N2 - Continued improvements in the treatment of pulmonary infections have paradoxically resulted in a growing challenge of individuals with postinfectious pulmonary complications (PIPCs). PIPCs have been long recognized after tuberculosis, but recent experiences such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic have underscored the importance of PIPCs following other lower respiratory tract infections. Independent of the causative pathogen, most available studies of pulmonary infections focus on short-term outcomes rather than long-term morbidity among survivors. In this document, we establish a conceptual scope for PIPCs with discussion of globally significant pulmonary pathogens and an examination of how these pathogens can damage different components of the lung, resulting in a spectrum of PIPCs. We also review potential mechanisms for the transition from acute infection to PIPC, including the interplay between pathogen-mediated injury and aberrant host responses, which together result in PIPCs. Finally, we identify cross-cutting research priorities for the field to facilitate future studies to establish the incidence of PIPCs, define common mechanisms, identify therapeutic strategies, and ultimately reduce the burden of morbidity in survivors of pulmonary infections.
AB - Continued improvements in the treatment of pulmonary infections have paradoxically resulted in a growing challenge of individuals with postinfectious pulmonary complications (PIPCs). PIPCs have been long recognized after tuberculosis, but recent experiences such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic have underscored the importance of PIPCs following other lower respiratory tract infections. Independent of the causative pathogen, most available studies of pulmonary infections focus on short-term outcomes rather than long-term morbidity among survivors. In this document, we establish a conceptual scope for PIPCs with discussion of globally significant pulmonary pathogens and an examination of how these pathogens can damage different components of the lung, resulting in a spectrum of PIPCs. We also review potential mechanisms for the transition from acute infection to PIPC, including the interplay between pathogen-mediated injury and aberrant host responses, which together result in PIPCs. Finally, we identify cross-cutting research priorities for the field to facilitate future studies to establish the incidence of PIPCs, define common mechanisms, identify therapeutic strategies, and ultimately reduce the burden of morbidity in survivors of pulmonary infections.
KW - bronchiectasis
KW - pneumonia
KW - tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85202906612&partnerID=8YFLogxK
U2 - 10.1513/AnnalsATS.202406-651ST
DO - 10.1513/AnnalsATS.202406-651ST
M3 - Review article
C2 - 39051991
AN - SCOPUS:85202906612
SN - 2329-6933
VL - 21
SP - 1219
EP - 1237
JO - Annals of the American Thoracic Society
JF - Annals of the American Thoracic Society
IS - 9
ER -